Literature DB >> 29708143

Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine.

Masaru Katoh1.   

Abstract

Entities:  

Year:  2018        PMID： 29708143      PMCID： PMC5906241          DOI： 10.21037/jtd.2018.03.62

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  39 in total

1.  Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.

Authors:  Daniel B Costa
Journal:  Transl Lung Cancer Res       Date:  2016-06

2.  The integration of genomics testing and functional proteomics in the era of personalized medicine.

Authors:  Masaru Katoh
Journal:  Expert Rev Proteomics       Date:  2017-10-23       Impact factor: 3.940

3.  Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Authors:  Valsamo Anagnostou; Kellie N Smith; Patrick M Forde; Noushin Niknafs; Rohit Bhattacharya; James White; Theresa Zhang; Vilmos Adleff; Jillian Phallen; Neha Wali; Carolyn Hruban; Violeta B Guthrie; Kristen Rodgers; Jarushka Naidoo; Hyunseok Kang; William Sharfman; Christos Georgiades; Franco Verde; Peter Illei; Qing Kay Li; Edward Gabrielson; Malcolm V Brock; Cynthia A Zahnow; Stephen B Baylin; Robert B Scharpf; Julie R Brahmer; Rachel Karchin; Drew M Pardoll; Victor E Velculescu
Journal:  Cancer Discov       Date:  2016-12-28       Impact factor: 39.397

Review 4.  Therapeutics Targeting FGF Signaling Network in Human Diseases.

Authors:  Masaru Katoh
Journal:  Trends Pharmacol Sci       Date:  2016-10-27       Impact factor: 14.819

Review 5.  MYC, Metabolism, and Cancer.

Authors:  Zachary E Stine; Zandra E Walton; Brian J Altman; Annie L Hsieh; Chi V Dang
Journal:  Cancer Discov       Date:  2015-09-17       Impact factor: 39.397

Review 6.  Targeting T Cell Co-receptors for Cancer Therapy.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 7.  Epigenetic modulators, modifiers and mediators in cancer aetiology and progression.

Authors:  Andrew P Feinberg; Michael A Koldobskiy; Anita Göndör
Journal:  Nat Rev Genet       Date:  2016-03-14       Impact factor: 53.242

Review 8.  Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.

Authors:  Masaru Katoh
Journal:  Epigenomics       Date:  2015-09-28       Impact factor: 4.778

Review 9.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

Review 10.  Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Authors:  Véronique Gelsi-Boyer; Mandy Brecqueville; Raynier Devillier; Anne Murati; Marie-Joelle Mozziconacci; Daniel Birnbaum
Journal:  J Hematol Oncol       Date:  2012-03-21       Impact factor: 17.388
View more
  3 in total

1.  Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer.

Authors:  Masaru Katoh
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 2.  Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.

Authors:  Jan Philipp Bewersdorf; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Anticancer Ther       Date:  2019-03-19       Impact factor: 4.512

3.  Using Machine Learning Modeling to Explore New Immune-Related Prognostic Markers in Non-Small Cell Lung Cancer.

Authors:  Jiasheng Xu; Han Nie; Jiarui He; Xinlu Wang; Kaili Liao; Luxia Tu; Zhenfang Xiong
Journal:  Front Oncol       Date:  2020-10-30       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.